Review of CheckMate-214: Long-term follow-up in favorable risk subgroup

Opinion
Video

Rana McKay, MD, examines the pivotal efficacy and safety outcomes from the 8-year follow-up of the CheckMate-214 trial in treatment-naïve patients, presented at ASCO GU 2024, and discusses how these findings impact clinical practice.

  1. Dr McKay: Please briefly review the key efficacy and safety data from the CheckMate-214 trial 8-year follow-up for treatment-naïve patients (Tannir NM, et al. J Clin Oncol. 2024) recently presented at ASCO GU 2024.
    • What are the clinical implications of these data in your practice?
    • In responders, how important is the durability of the response (OS and PFS) for both the intermediate/poor and favorable-risk groups?
Recent Videos
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Martin H. Voss, MD, an expert on kidney cancer
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Corey Cutler, MD, MPH, and Hannah Choe, MD, experts on GVHD
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer
2 KOLs are featured in this program.
2 KOLs are featured in this program.
Related Content